VoxelCloud Strengthens Global Strategy with Top-Tier Scientific Advisory Board to Enable Precision Disease Prevention for Overseas Commercial Health Insurers

Chinese medical AI companies have significantly enhanced their research capabilities and technological prowess, leading global development in this field. In recent years, China’s medical AI industry has shown a growth trend, with multiple sector leaders completing initial public offerings (IPOs).

Since the beginning of this year, several companies in China’s AI medical imaging sector have filed prospectuses, ushering the industry into a new stage of development.

AI-assisted diagnosis has demonstrated significant value and gained widespread adoption in healthcare institutions. One of the macro trends in this field is the expansion from diagnostic applications to risk control, and from hospitals to medical insurance systems. The integration of imaging data with clinical indicators will provide medical insurance programs with more in-depth and reliable bases for disease risk assessment and the inclusion of preventive screening. This enables proactive examination and early intervention for redefined high-risk populations through a personalized reimbursement framework, thereby achieving a win-win outcome for both patients and medical insurance funds.

Currently, numerous leading companies are engaging in close collaboration with overseas experts through the establishment of expert committees and other initiatives.

Taking VoxelCloud, a leading domestic medical AI enterprise, as an example, to facilitate predictions of the risks linking chronic metabolic diseases with cardiac, cerebrovascular, and renal conditions, as well as early cancer screening, its Scientific Advisory Committee has added five top experts in ophthalmology, cardiology, and radiological imaging: Dr. Sophie J. Bakri, Director of Ophthalmology at Mayo Clinic; Professor Matt Budoff, Director of Cardiac CT at UCLA Medical Center; Dr. Gregory N. Nicola, Chair of Health Economics at the American College of Radiology (ACR); Professor Michael J. Blaha, Associate Editor of the Journal of Cardiovascular Computed Tomography (JCCT) from Johns Hopkins University; and Professor Pam R. Taub from the UCSD School of Medicine.

Five experts will serve as the Scientific Advisory Board to guide VoxelCloud’s global development strategy in AI medical imaging and oversee the execution of research conducted by its scientific teams. The Scientific Advisory Board will also provide guidance, opinions, and feedback on the development of new products in the field of AI medical imaging, and support VoxelCloud in building its medical talent pool in both the Chinese and global markets.

What support will overseas experts provide to AI medical imaging companies once domestic enterprises establish collaborative ties with them? How can domestic enterprises leverage these collaborations to expand into overseas markets?

Gaining recognition from overseas experts is often a testament to a company’s comprehensive capabilities.

In the past, Chinese companies were still in a phase of accumulating technology and experience, generally perceived as following overseas innovations rather than ranking among global innovators. The growing trend of top-tier overseas experts choosing to collaborate with Chinese enterprises demonstrates that this longstanding stereotype is gradually being dismantled. The influence of Chinese companies has now extended beyond borders, earning global recognition.

Professor Matt Budoff is from the David Geffen School of Medicine in the United States. He serves as the Director of Cardiac CT in the Division of Cardiology at the Harbor-UCLA Medical Center in Torrance, California. Dr. Budoff has served as the principal investigator for numerous medical research trials and is a Senior Fellow of the American College of Cardiology (FACC). As early as ten years ago, Dr. Budoff received the Einstein Award for Scientific Achievement from the International Biographical Centre in Cambridge, UK. He also won the Best Oral Abstract Award at the 2009 American Heart Association Scientific Sessions and was listed among the Top Doctors by U.S. News & World Report in 2011.

Dr. Sophie J. Bakri is the Chair of the Department of Ophthalmology at Mayo Clinic. She is a specialist in retinal and vitreous diseases and surgery, with particular expertise in age-related macular degeneration, diabetic retinopathy, venous occlusive disorders, and the repair of complex retinal detachments. Dr. Bakri has served as the Program Chair and a member of the Executive Committee of the Macula Society, as well as a member of the Board of Directors and the Program Committee of the American Society of Retina Specialists.

The addition of top-tier experts affirms Voxel Technology’s existing capabilities and future potential. In China, Voxel Technology’s AI-powered products have gained widespread recognition, establishing collaborations with over 650 hospitals affiliated with the National Standardized Metabolic Disease Management Center (MMC) and enabling AI-based screening services for more than 200,000 patients with diabetes.

Following the establishment of the new team, VoxelCloud will accelerate its exploration of AI-based screening in overseas markets, leveraging its expertise to help more patients detect diseases early and receive timely treatment.

While consolidating its AI-assisted screening business, VoxelTech is also exploring the development of innovative application scenarios. The addition of Dr. Michael J. Blah, Dr. Pam R. Taub, and Dr. Gregory Nicola aims to accelerate the exploration of these innovative scenarios.

Michael J. Blaha, MD, MHS, Professor of Cardiology and Epidemiology at Johns Hopkins University, is the Director of Clinical Research at the Ciccarone Center for the Prevention of Cardiovascular Disease, Associate Editor of the Journal of Cardiovascular Computed Tomography (JCCT), a standing member of the FDA Endocrine and Metabolic Drugs Advisory Committee (EMDAC), Principal Investigator of the Coronary Artery Calcium Consortium, and Co-Chair of the Cross-Cohort Collaboration.

Dr. Pam R. Taub is an expert in the prevention of heart disease, coronary artery disease, and heart failure. She serves as the Founding Director of the Step Family Foundation Center for Cardiac Rehabilitation and Wellness at Jacobs Medical Center, and is a Fellow and Board Member of the American College of Preventive Cardiology in California.

Dr. Gregory Nicola is the ACR Chair Expert in Health Economics, with over 20 years of experience in clinical and healthcare leadership within both academic and private medical sectors. In addition to serving as Chief Medical Officer at NeuTigers, where he oversees the development of a medical edge AI platform, Dr. Nicola is a practicing neuroradiologist and attending radiologist at a major hospital network in New Jersey.

The addition of five experts focuses on providing guidance and feedback for the implementation of VoxelTech’s artificial intelligence solutions in the U.S. insurance industry. In this sector, VoxelTech is leveraging AI to analyze and process insurance data, offering insurance pricing and risk control solutions.

Moving from the familiar domestic market to unfamiliar overseas markets, companies must understand and respect local demographic characteristics, clinical pathways, and relevant guidelines for health insurance reimbursement. Only with a thorough understanding of existing systems can medical AI companies effectively empower them—this is the significance of introducing experts into medical AI enterprises.

For AI enterprises like VoxelCloud, which have been expanding overseas for several years, the addition of experts will deepen their brand influence, product R&D, and clinical understanding. In the near future, VoxelCloud may accelerate the development of medical AI and deploy it in more effective healthcare scenarios.